Luyan Pharma Co Ltd (002788) Fair Value & Analysis
Healthcare · CN · Market cap 4.4B CNY (≈ $653M) · ISIN CNE1000025W1
What is Luyan Pharma Co Ltd really worth?
A solid business, trading 31% below our fair value of ¥15.91.
Strengths
Risks
For context
Fair value as of: Sep 5, 2026
From 26 valuation models · updated today
Share price +2.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (¥9.82 to ¥19.88) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.
How to read this chart
60‑month range ¥5.90 – ¥27.49 · fair‑value band ¥9.82 – ¥19.88 · the ¥10.96 price screens below the ¥15.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.
Analysis
Luyan Pharma Co Ltd (002788) currently trades at ¥10.96, while our model-based Fair Value estimate is ¥15.91, implying the stock looks roughly 31.1% undervalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of ¥22.45 per share, and 21 of the 26 models we run sit above the ¥10.96 price. Bear case: the Asset-Based group reads lowest at ¥5.70, and 5 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Luyan Pharma Co Ltd generated revenue of 21.4B CNY at a net margin of 1.3%. Revenue grew 3.4% year over year. It earns a return on equity of 8.3%. Net debt stands at 3.8B CNY. Fundamentals as of Sep 5, 2026
Our scenario range runs from ¥9.82 (bear case) to ¥19.88 (bull case); at ¥10.96, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 61% below its 52-week high and 40% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at 45%, 002788 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.2436 per share, which is 1.5 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth DCF (¥22.45) versus Asset-Based (¥5.70). Highest evidence: FCF DCF (79).
Notify me when 002788 reaches fair value
Put 002788 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail chains.
Full company description
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail chains. The company was formerly known as Luyan (Fujian) Pharma Co. Ltd. and changed its name to Luyan Pharma Co.,Ltd. in June 2016. Luyan Pharma Co.,Ltd. was founded in 1992 and is headquartered in Xiamen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Luyan Pharma Co Ltd reported revenue of 21.2B CNY in FY2025 versus 17.5B CNY in FY2021, a compound +4.9%/yr. Reported net income was 281M CNY in FY2025, compounding −2.1%/yr from FY2021.
of which total revenue +14.0 % · buybacks/dilution −5.0 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch 002788: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 57 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.90 | ¥29.07 | +27% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.79 | ¥23.86 | +27% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | −71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | −21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | −19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | −38% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.30 | ¥5.91 | −56% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
Compare Luyan Pharma Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Luyan Pharma Co Ltd (002788) overvalued or undervalued?
What is the fair value of 002788?
What is the quality score of 002788?
What is the revenue of Luyan Pharma Co Ltd (002788)?
What is the net profit margin of 002788?
Does Luyan Pharma Co Ltd pay a dividend?
Watch Luyan Pharma Co Ltd in the live analysis
One click puts Luyan Pharma Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.